
Our people are our strength. And together with over 54,000 colleagues, we're creating the next breakthrough in the world of healthcare and innovation for both humans and animals. Are you ready to join us? #LifeForward Privacy Notice: https://www.boehringer-ingelheim.com/privacy-notice Imprint: https://www.boehringer-ingelheim.com/imprint
Unlock the market timeline & signal feed
428 signals in the last 90 days.
The order this company entered each market — oldest to newest
35 active postings
14 active postings
Sign up to see the full signal feed
How Boehringer Ingelheim's international expansion compares to its competitors
Bars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
Boehringer IngelheimYou | 43 | 2 | +204% | 408 | 34 |
Gerente de Produto - Oncologia (Pulmão)
View postingSão Paulo, São Paulo, Brazil · yesterday
Medical Science Liaison, Quebec City
View postingQuebec, Canada · 2d ago
Talent Acquisition Process & Systems Manager
View postingIngelheim am Rhein, Rhineland-Palatinate, Germany · Full-time · yesterday
This is us. Is this you? Apply now
EndedObesity is a multi-organ metabolic disease, not just a lifestyle choice. Addressing its biology enables coordinated care, supporting earlier intervention, better comorbidity management, and stronger patient outcomes.
EndedObesity is a multi-organ metabolic disease, not just a lifestyle choice. Addressing its biology enables coordinated care, supporting earlier intervention, better comorbidity management, and stronger patient outcomes.
EndedNo recent news
Sign up to track this company and get alerted the moment something changes.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Boehringer Ingelheim's business, markets, and growth signals.

© 2026 Pubrio. All rights reserved.